← All organizations
Highest phase reached
Phase 3
First clinical trial
Sep 1, 2007Last known activity
Feb 1, 2026
Timeline
1990s
- Jun 1, 1991
Gateway for Cancer Research— Founded
Drugs by trial phase (68 distinct, 30 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (50 own, 0 via acquisition)
Phase 1 (15 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Studied for
- Acute Disease
- Adenocarcinoma
- Adenocarcinoma, Mucinous
- Bone Neoplasms
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma, Signet Ring Cell
- Colonic Neoplasms
- Cystadenocarcinoma
- Genital Neoplasms, Female
- Genital Neoplasms, Male
- Glioblastoma
- Glioma
- Gliosarcoma
- Graft vs Host Disease
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lip Neoplasms
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Multiple Myeloma
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Osteosarcoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Rectal Neoplasms
- Recurrence
- Skin Neoplasms
- Thyroid Neoplasms
- Urologic Neoplasms
Recent trials (30)
- NCT07283848CollaboratorPhase 2Feb 1, 2026
- NCT07021989CollaboratorPhase 2Oct 31, 2025
- NCT07053085CollaboratorPhase 2Sep 17, 2025
- NCT06263153CollaboratorPhase 2Nov 1, 2024
- NCT06268015CollaboratorPhase 2Oct 1, 2024
- NCT06200155CollaboratorPhase 2Apr 16, 2024
- NCT05669846CollaboratorPhase 2Sep 30, 2023
- NCT06030037CollaboratorPhase 2Sep 30, 2023
- NCT05292664CollaboratorPhase 1Dec 31, 2022
- NCT05318469CollaboratorPhase 2Sep 10, 2022
- NCT05053750CollaboratorEarly Phase 1Mar 31, 2022
- NCT05029999CollaboratorPhase 1Dec 31, 2021
- NCT04898894CollaboratorPhase 1Nov 15, 2021
- NCT04716725CollaboratorPhase 2Sep 28, 2021
- NCT04483206CollaboratorPhase 1Dec 21, 2020
Details
- Founded
- Schaumberg, IL, US Jun 1, 1991
- Last known activity
- Feb 1, 2026